Novo Nordisk CagriSema beats Mounjaro in weight-loss trial

Novo Nordisk's CagriSema showed 12% average weight loss versus 9% for tirzepatide (Mounjaro) in a head-to-head study. This is a competitive setback for Eli Lilly's leading GLP-1 drug, potentially shifting market share in the obesity treatment space. Details on trial size and statistical significance are not provided, so the magnitude of the advantage remains uncertain.